Webinar – Launch and publishing of the Guideline for Treatment of Leishmaniasis in the Americas

Webinar – Launch and publishing of the Guideline for Treatment of Leishmaniasis in the Americas
Webinar – Launch and publishing of the Guideline for  Treatment of Leishmaniasis in the Americas

Leishmaniases remains neglected infectious diseases of great importance, as they mainly affect the poorest people with the least access to health services. In the Americas, it is a public health problem due to its morbidity, mortality, and wide geographical distribution.

PAHO presents the Guideline for the Treatment of Leishmaniasis in the Americas, which is the result of joint work with experts from the Region. This publication presents the update of the therapeutic recommendations, detailing the schemes and criteria for the indication of treatment for cutaneous, mucosal, and visceral leishmaniasis in the regional context, in accordance with the standards for the development of PAHO/WHO guidelines, using the GRADE methodology. Thus, some of the recommendations presented for the Americas may differ from the specific recommendations from other continents in view of the distinct epidemiological and biological aspects, such as the different circulating species of Leishmania, transmission cycles and therapeutic responses.


Date: tuesday, June 28, 2022
Time: 3:00 pm (EDT – Eastern Daylight Time. USA and Canada)
Plataform: Zoom 
Simultaneous interpretation in Spanish, English and Portuguese

watch the recording event


Agenda

  • 03:00 - 03:05 pm Opening of the activities
    Ana Nilce Elkhoury - PAHO/WHO
  • 03:05 - 03:15 pm Opening remarks
    Luís Gerardo Castellanos - PAHO/WHO
  • 03:15 - 03:25 pm GRADE methodology: process of elaboration of the Guideline
    Ana Marcela Torres – PAHO/WHO
  • 03:25 - 03:35 pm Important differences between the 2013 treatment recommendations and the current
    Ana Nilce Elkhoury – PAHO/WHO
  • 03:35 - 03:40 pm Presentation of the leishmaniasis video
  • 03:40 - 03:55 pm Main treatment recommendations for cutaneous and mucosal leishmaniasis
    Jaime Soto – Funderma y Dermatological Hospital of Jorochito, Bolivia
  • 03:55 - 04:05 pm Treatment recommendations for visceral leishmaniasis
    Dorcas Lamounier Costa – Federal University of Piauí, Brazil
  • 04:05 - 04:15 pm PAHO/WHO Strategic Fund: Antileishmaniasis drugs and other supplies
    Nora Giron – PAHO/WHO
  • 04:15 - 04:20 pm Final comments and closure of the activities
    Ana Nilce Elkhoury – PAHO/WHO
     

download the agenda